|
In recent years the market for peptide-based pharmaceuticals has been growing rapidly. As of 2005 an estimated 40 peptide-based pharmaceutical products were on the market with approximately 270 more in different phases of clinical trials (1,2). The peptide market has been bolstered by improvements in large-scale manufacturing and the emergence of alternative routes of administration including nasal and oral delivery technologies.
Unigene’s technologies for the large-scale recombinant manufacturing of peptides and formulations for compliance-friendly delivery are capable of being applied to a wide variety of peptide and protein-based therapeutics. The company’s clinical and R&D peptide programs cover therapeutic areas of osteoporosis, osteoarthritis, satiety/obesity, endometriosis, prostate cancer, pain, site-directed bone growth (SDBG), and diabetes.
- Sehgal, A. (2004) Therapeutic Peptides: Applications in the Treatment of Human Disease. D&MD Publications.
- (2004) Strategic Analysis of the Therapeutic Peptides Market in Europe. Frost and Sullivan Research Reports.
|
